Phase 2 CANAL (Chronic Cough in IPF) Planned Interim Statistical Update 1Q 2022, with Top-Line Data 1H 2022
Phase 2b/3 PRISM (Chronic Pruritus in PN) Enrollment to End January 31, 2022, with Top-Line Data 1H 2022
NEW HAVEN, Conn., Jan. 5, 2022 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that it expects to perform an interim statistical update in the first quarter of 2022 for its ongoing Phase 2 CANAL trial of Haduvio in patients suffering from chronic cough due to idiopathic pulmonary fibrosis (IPF). Trevi also announced that it expects to end enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) by January 31, 2022.